CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study - PubMed
3 days ago
- #CAR-T cell therapy
- #acute leukemia
- #anti-HLA antibody desensitization
- This pilot clinical study evaluated CD19/BCMA-targeted CAR-T cell therapy for desensitizing anti-HLA antibodies in acute leukemia patients before transplantation.
- Seven patients with acute leukemia (four AML, three B-ALL) were treated, six with CD19 CAR-T cells and one with BCMA CAR-T cells, with no severe neurotoxicity or cytokine release syndrome observed.
- CAR-T cell expansion occurred in six patients (86%), and among seven with pre-infusion anti-HLA-I antibodies, five showed decreased MFI, including three with over 75% reduction.
- In three patients with donor-specific anti-HLA antibodies (DSAs) before CAR-T infusion, the median DSA MFI level significantly declined post-treatment, and two underwent combined desensitization before stem cell transplantation.
- The study suggests potential safety and efficacy of CD19 and BCMA CAR-T cells for anti-HLA antibody desensitization, but larger sample sizes are needed for further evaluation, especially for BCMA CAR-T therapy.